?>
Contact us
Follow Us
About Us
Members
Executive Director
Why Biosimilars
The Issue
Our Solutions
Biosimilars 101
Foundations
Core Principles
FDA Regulatory Tenets
Biosimilars FAQs
Future Evolution of Biosimilar Development
Approved Biosimilars
Advocacy
Our Action
Tools
News
Resources
Get Involved
Partners
Archives:
Resources
Get more out of your business.
Reach it with Microsoft Dynamics 365 Business Central.
July 3, 2019
Katie Quinn
Five Things to Know About Biosimilars
July 3, 2019
Katie Quinn
Awareness, Knowledge & Perceptions of Biosimilars among Specialty Physicians
July 3, 2019
Katie Quinn
States Continue to Pass Biosimilar Substitution Laws in 2018
July 3, 2019
Katie Quinn
FDA Guidance: Additional Q&A Regarding Implementation of the BPCIA (2021)
July 3, 2019
Katie Quinn
FDA Guidance: Q&A Regarding Implementation of the BPCIA (2021)
July 3, 2019
Katie Quinn
FDA Draft Guidance: Reference Product Exclusivity
July 3, 2019
Katie Quinn
FDA Draft Guidance: Clinical Pharmacology Data Use
July 3, 2019
Katie Quinn
FDA Guidance: Quality Considerations for Demonstrating Biosimilarity
July 3, 2019
Katie Quinn
FDA Guidance: Scientific Considerations in Demonstrating Biosimilarity
July 3, 2019
Katie Quinn
Biosimilars: More Treatment Choices and Innovation
01
02
03
04